Carterra is Biotechnology in United States that focus on monoclonal antibody business. Founded in 2005. They cover business area such as developer, biosensor platform, novel therapeutic candidate, mAb) characterization platform, patent microfluidic technology, real-time High Throughput Surface Plasmon Resonance, (HT-SPR, Kinetic and Epitope analysis, visualization software, pharmaceutical and biotechnology client.
2005
( 19 years old in 2024 )
Monoclonal Antibody
-
825 North 300 West
Suite C309
Salt Lake City, UT 84103
United States
Private
developerbiosensor platformnovel therapeutic candidatemAb) characterization platformpatent microfluidic technologyreal-time High Throughput Surface Plasmon Resonance(HT-SPRKinetic and Epitope analysisvisualization softwarepharmaceutical and biotechnology client
* We use standard office opening hours in near Carterra's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Carterra is Biotechnology business from United States that founded in 2005 (19 years old in 2024), Carterra business is focusing on Monoclonal Antibody.
Carterra headquarter office and corporate office address is located in 825 North 300 West Suite C309 Salt Lake City, UT 84103 United States.
Carterra was founded in United States.
In 2024, Carterra is currently focus on monoclonal antibody sector.
Above is snippet of Google Trends for "monoclonal antibody" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Carterra, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
